Bioventus (BVS) AI Stock Analysis

• Market Cap: $525.72M
• Dividend Yield: N/A
• Average Volume (3M): 420.87K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.78
• Revenue Growth: 8.60%
• EPS Growth: -42.76%
• Country: US
• Employees: 930
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Devices
• EPS (TTM): 0.08
• Shares Outstanding: 66,357,610
• 10 Day Avg. Volume: 410,397
• 30 Day Avg. Volume: 420,869
• PEG Ratio: -2.47
• Price to Book (P/B): 3.03
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 18.89
• Enterprise Value/Market Cap: 1.47
• Enterprise Value/Revenue: 0.35
• Enterprise Value/Gross Profit: 2.03
• Enterprise Value/Ebitda: 5.54
• 1Y Price Target: $11.33
• Price Target Upside: 77.03% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 47 Neutral
• Price Target: $6.00 ▼(-6.25%Downside)

Bioventus's stock score is primarily impacted by its financial struggles, with ongoing profitability issues and high leverage. The technical analysis further indicates bearish sentiment. While the earnings call provided a positive outlook on strategic initiatives, the underlying financial and valuation metrics remain concerning.

Positive Factors

Business Execution

The company is shifting from a recovery story to an execution story, succeeding in improving commercial execution across major business units.

Cash Flow

Bioventus is expected to deliver significant cash flow acceleration by lowering inventory, interest expense, and one-time cash costs.

Negative Factors

Earnings Pressure

Adjusted EBITDA should be weaker due to revenue headwinds and more normalized expense levels expected compared to reduced spending previously.

Revenue Challenges

Q1/H1 organic revenues should be more challenged given two fewer selling days, a pull-forward of HA orders, and continued BGS distributor choppiness.

Bioventus Business Overview & Revenue Model

Company Description

Bioventus Inc. (BVS) is a medical device company that specializes in developing and commercializing clinically effective and cost-efficient solutions for bone healing, bone graft, joint therapies, and biologics. The company primarily operates in the healthcare sector, focusing on orthopedic solutions that enhance patient outcomes and reduce healthcare costs. Bioventus offers a diverse portfolio of products, including minimally invasive therapies for osteoarthritis, bone graft substitutes, and devices that stimulate bone growth.

How the Company Makes Money

Bioventus generates revenue through the sale of its medical devices and biologic products to healthcare providers, including hospitals, clinics, and orthopedic specialists. The company's key revenue streams include product sales in the areas of bone healing, joint pain treatment, and bone graft solutions. Bioventus collaborates with healthcare professionals to ensure the effective integration of their products into treatment regimes, thereby driving sales. Additionally, Bioventus may engage in strategic partnerships and licensing agreements to expand its product offerings and market reach, which can also contribute to its earnings.

Bioventus Financial Statement Overview

Summary

Bioventus is facing financial difficulties with negative EBIT and net income margins. High leverage and declining revenues highlight financial risks, despite a stable gross profit margin and positive cash flow.

Income Statement

Bioventus has faced challenges with profitability, as evidenced by negative EBIT and net income margins in TTM (Trailing-Twelve-Months). Despite a stable gross profit margin around 67%, the company struggles with operating efficiency. The revenue growth rate shows a declining trend, indicating potential sales stagnation.

Balance Sheet

The debt-to-equity ratio is significantly high at 2.33 in TTM, suggesting high leverage and potential financial risk. However, the equity ratio stands at 21.4%, indicating a moderate proportion of equity financing. The negative return on equity reflects ongoing profitability issues.

Cash Flow

The cash flow statement reveals a positive free cash flow, yet it's decreasing year-over-year, indicating diminishing cash generation capacity. The operating cash flow to net income ratio is positive, showing some efficiency in converting earnings into cash, despite overall negative net income.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	573.28M	512.35M	512.12M	430.90M	321.16M
Gross Profit	388.23M	328.19M	331.08M	302.71M	233.52M
EBITDA	-49.55M	-23.07M	-121.61M	45.48M	52.06M
Net Income	-33.54M	-156.23M	-158.70M	19.38M	16.41M
Balance Sheet
Total Assets	727.96M	810.91M	1.37B	1.23B	494.47M
Cash, Cash Equivalents and Short-Term Investments	41.58M	36.96M	30.19M	43.93M	86.84M
Total Debt	335.63M	394.85M	418.07M	357.68M	188.38M
Total Liabilities	542.35M	589.79M	960.43M	692.07M	350.31M
Stockholders Equity	147.94M	173.59M	325.24M	458.92M	144.16M
Cash Flow
Free Cash Flow	37.79M	7.98M	-25.06M	15.62M	51.13M
Operating Cash Flow	38.80M	15.34M	-13.54M	22.99M	71.80M
Investing Cash Flow	22.96M	15.81M	-116.44M	-283.76M	-20.50M
Financing Cash Flow	-54.58M	-26.65M	62.08M	273.37M	-29.57M

Bioventus Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BVS, the sentiment is Negative. The current price of 6.4 is below the 20-day moving average (MA) of 6.74, below the 50-day MA of 6.66, and below the 200-day MA of 9.38, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 42.54 is Neutral, neither overbought nor oversold. The STOCH value of 17.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BVS.

Bioventus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KIDS	68 Neutral	$563.74M	―	-11.33%	―	31.28%	-81.86%
AXGN	63 Neutral	$601.64M	―	-7.22%	―	18.81%	67.41%
SIBN	61 Neutral	$739.79M	―	-15.96%	―	22.60%	41.26%
Sector *	60 Neutral	HK$17.07B	6.10	-7.44%	2.88%	11.55%	-28.15%
AVNS	52 Neutral	$549.38M	45.80	-36.78%	―	1.34%	-530.36%
OFIX	51 Neutral	$450.58M	―	-27.82%	―	5.85%	-8.92%
BVS	47 Neutral	$525.72M	―	-19.79%	―	8.60%	-42.76%

Bioventus Corporate Events

Bioventus Holds Annual Meeting, Elects Directors

On June 3, 2025, Bioventus, Inc. held its Annual Meeting of Stockholders, where approximately 89.76% of the outstanding shares were represented. During the meeting, stockholders elected Class I directors to the Board and ratified Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (BVS) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Bioventus stock, see the BVS Stock Forecast page.